Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,047 shares of the biopharmaceutical company’s stock after selling 280 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,203,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares in the last quarter. TD Asset Management Inc boosted its stake in Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after acquiring an additional 166,998 shares during the last quarter. Finally, Swedbank AB acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth $129,257,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $4.12 during trading on Friday, hitting $933.02. The company had a trading volume of 547,777 shares, compared to its average volume of 504,705. The business has a 50 day moving average of $1,088.44 and a 200 day moving average of $1,040.53. The firm has a market capitalization of $102.86 billion, a price-to-earnings ratio of 24.71, a P/E/G ratio of 3.29 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the prior year, the business posted $8.79 EPS. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Wells Fargo & Company decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,101.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.